Carisbamate
Phase 3Small molecule
Carisbamate is one of 32 small molecule programs targeting Seizure. It is currently in Phase 3.
1
Indications
11
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
33 competitors in Seizure
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Vimpat
UCBApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Epidiolex
Jazz PharmaceuticalsApproved
Tegretol
NovartisApproved
Trileptal
NovartisApproved
Fycompa
CCatalyst Biosciences
Approved
Zonegran
AAzurity Pharmaceuticals
Approved
Topamax
WWim Janssens
Approved
Lamictal
GGlaxo Dba Glaxosmithkline
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Seizure4 trials
Lennox-Gastaut syndrome2 trials
Epilepsy1 trial
Alcohol Dependence1 trial
Carisbamate as a Potential Treatment for Alcohol Dependence
Completed·—·Phase 1/2·NCT02435381·11 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carisbamate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSK Life Science, Inc.